Point‐of‐care laboratory halves door‐to‐therapy‐decision time in acute stroke
暂无分享,去创建一个
Yang Liu | Klaus Fassbender | Thomas Bertsch | Wolfgang Reith | I. Grunwald | W. Reith | K. Fassbender | T. Bertsch | C. Roth | P. Papanagiotou | M. Lesmeister | J. Geisel | I. Keller | S. Walter | P. Kostopoulos | A. Haass | S. Helwig | Yang Liu | Anton Haass | Iris Grunwald | Juergen Geisel | Martin Lesmeister | Silke Walter | Panagiotis Papanagiotou | Christian Roth | Panagiotis Kostopoulos | Isabel Keller | Stephan Helwig | Mihaela Grasu | Carmen Becker | Sarah Kaffiné | Annika Leingärtner | M. Grasu | C. Becker | Sarah Kaffiné | Annika Leingärtner | Martin Lesmeister
[1] P. Moerloose,et al. Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients , 2001, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[2] Yang Liu,et al. "Mobile stroke unit" for hyperacute stroke treatment. , 2003, Stroke.
[3] Adnan I. Qureshi,et al. Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .
[4] M. Hill,et al. Reliability of Point-of-Care Testing of INR in Acute Stroke , 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[5] E. Dooley. National Institute of Neurological Disorders and Stroke , 2006 .
[6] I. Grunwald,et al. Bringing the Hospital to the Patient: First Treatment of Stroke Patients at the Emergency Site , 2010, PloS one.
[7] Gary A. Ford,et al. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.
[8] Gregory W Albers,et al. Intravenous alteplase for ischaemic stroke , 2007, The Lancet.
[9] S. Gutnikov,et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) , 2005, The Lancet.
[10] S. Heiland,et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma , 2011, Annals of neurology.
[11] Mario Zuccarello,et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.
[12] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[13] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[14] A. Beckett,et al. AKUFO AND IBARAPA. , 1965, Lancet.
[15] Joanne Gray,et al. Systematic review of stroke thrombolysis service configuration , 2009, Expert review of neurotherapeutics.
[16] K. Hossmann. Viability thresholds and the penumbra of focal ischemia , 1994, Annals of neurology.
[17] Gregory W Albers,et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.
[18] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[19] J. Grotta,et al. Early stroke treatment associated with better outcome: the ninds rt-pa stroke study , 2000, Neurology.
[20] W. Hacke,et al. Point‐of‐care reversal treatment in phenprocoumon‐related intracerebral hemorrhage , 2010, Annals of neurology.
[21] G. Moneta,et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) , 2007 .
[22] W. Hacke,et al. Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral Anticoagulants , 2009, Stroke.